Profund Advisors’s LB Pharmaceuticals LBRX Stock Holding History

Profund Advisors’s Portfolio LBRX Stock Details LBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.08M	Buy	+28,203	New	+$1.17M	0.03%	336

Other funds holding LBRX

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Sigma Planning Corp Ann Arbor, Michigan $3.88B AUM 23.38% 1-Year Est. Return

Meyer Handelman Company Rye Brook, New York $3.49B AUM 26.82% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $84.4B AUM 20.16% 1-Year Est. Return

Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

State of Wyoming Cheyenne, Wyoming $1.29B AUM 32.25% 1-Year Est. Return

Profund Advisors's LBRX Position: Q3 2026 in Review

Profund Advisors opened a new position in LB Pharmaceuticals (LBRX) in Q3 2026: 28,203 shares worth $1.08M. The stake represents 0.03% of the portfolio and ranks #336 among its holdings.

19 funds tracked by Wall St. Rank hold LBRX as of Q3 2026.

Profund Advisors held 28,203 shares of LB Pharmaceuticals worth $1.08M as of Q3 2026.
LB Pharmaceuticals was a new Profund Advisors position in Q3 2026.
LB Pharmaceuticals made up 0.03% of Profund Advisors's portfolio in Q3 2026, its #336 holding.
19 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q3 2026.

Based on Profund Advisors's 13F filing for Q3 2026, filed 29 Oct 2026.